Etude du Microenvironnement médullaire Dans Les Leucémies Aiguës de l'Enfant
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.
• for patients with AL:
‣ Child with acute lymphoblastic or myeloblastic leukemia at diagnosis
⁃ Not having received prior hematological treatment
⁃ Aged 1 to 15 years old
⁃ Whose 2 parents, or the holder of parental authority, have signed a consent enlightened.
⁃ Affiliated patient or beneficiary of a social security scheme.
• Control group patients:
‣ Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis).
⁃ Aged between 1 and 15 years old.
⁃ Having no pathology of hematological origin.
⁃ Not having received any treatment that could interfere with the functioning of the bone marrow.
⁃ Whose 2 parents or the holder of parental authority have signed a consent enlightened.
⁃ Affiliated patient or beneficiary of a social security scheme.